UK nears approval of first CBD foods while pending EU-alignment rules could shorten their shelf life

# Summary Britain is close to granting its first formal authorizations for ingestible CBD foods after a six-year regulatory process. The Food Standards Agency (FSA) is recommending approval of three novel-food applications that together cover roughly 3,000 products. The approvals, if finalized by ministers in England and Wales and followed by Scotland's sign-off, would give companies a clear path to market under UK rules.

# What the FSA recommended

# Conditions and intake limits Any approved products would operate under the FSA's provisional acceptable daily intake (ADI) for adults of 10 milligrams of CBD per day. That ADI is the basis for labeling and risk controls the FSA expects to attach to novel-food authorizations.

# The EU difference and the 2027 risk Authority (EFSA) set a lower provisional intake this year, equivalent to roughly 2 mg daily for a 70-kilogram adult. That divergence matters because the UK is negotiating sanitary and phytosanitary arrangements with the EU and plans implementation in 2027. If novel foods are covered without exception, existing UK authorizations would cease to apply and future CBD approvals in Britain would need to meet EU standards.

# Why this matters for businesses Companies that invested years and resources to meet UK novel-food requirements could face a second regulatory transition soon after authorization. EIHA's consortium approach lowered the per-company cost of toxicology work, but changing intake limits or other conditions under EU rules could require reformulation, relabeling, or withdrawal.

# Timing and decision path Sept. 16. If the board endorses them, the recommendations will go to ministers in England and Wales for final authorization. Scotland is processing the applications on its own timetable.

# Practical implications for product makers and retailers

• Products cleared under UK rules would have to comply with labeling and ADI restrictions tied to 10 mg/day.
• If the UK implements EU novel-food rules via the sanitary agreement, ADI and approval conditions could change to align with EFSA's lower provisional level, affecting allowable dosage per product.
• Companies should plan for a potential regulatory transition in 2027 rather than treating UK authorization as a long-term end state.

# Bottom line The near-term outcome: a likely set of UK novel-food authorizations that bring many CBD foods into a regulated market. The next practical risk: a planned 2027 implementation of UK-EU sanitary rules that could transfer CBD oversight to the EU regime and its stricter provisional intake, forcing further changes for producers and retailers.